FY2027 Earnings Forecast for Insmed Issued By HC Wainwright

Insmed, Inc. (NASDAQ:INSM) – Stock analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of Insmed in a research report issued on Monday, October 12th. HC Wainwright analyst A. Fein now expects that the biopharmaceutical company will post earnings of $1.63 per share for the year, up from their previous estimate of $1.62. HC Wainwright currently has a “Buy” rating and a $220.00 price objective on the stock. The consensus estimate for Insmed’s current full-year earnings is ($1.84) per share.

INSM has been the topic of a number of other research reports. Truist Financial restated a “buy” rating and set a $195.00 target price (up from $185.00) on shares of Insmed in a report on Monday, August 10th. Roth Capital reaffirmed a “buy” rating and issued a $198.00 price target (down from $212.00) on shares of Insmed in a research note on Tuesday, September 15th. Bank of America reiterated a “buy” rating and issued a $207.00 price target on shares of Insmed in a research report on Monday. Barclays reduced their price objective on shares of Insmed from $237.00 to $207.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 30th. Finally, Morgan Stanley restated an “overweight” rating and set a $218.00 price objective on shares of Insmed in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $200.30.

Insmed Trading Down 2.0%

NASDAQ INSM opened at $98.56 on Tuesday. The stock has a 50-day simple moving average of $120.20 and a 200 day simple moving average of $119.46. The company has a market capitalization of $21.52 billion, a PE ratio of -23.98 and a beta of 0.83. The company has a current ratio of 3.72, a quick ratio of 3.40 and a debt-to-equity ratio of 0.74. Insmed has a 12 month low of $90.39 and a 12 month high of $212.75.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.61. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%. The business had revenue of $425.49 million for the quarter, compared to analyst estimates of $395.50 million. During the same period last year, the company earned ($1.70) EPS. The firm’s revenue was up 296.1% on a year-over-year basis.

Insider Buying and Selling at Insmed

In other Insmed news, Director David Brennan sold 25,000 shares of Insmed stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the transaction, the director directly owned 39,238 shares in the company, valued at approximately $4,865,512. The trade was a 38.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Roger Adsett sold 239,850 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $133.27, for a total value of $31,964,809.50. Following the completion of the transaction, the chief operating officer directly owned 98,744 shares of the company’s stock, valued at approximately $13,159,612.88. The trade was a 70.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Insmed

Institutional investors and hedge funds have recently modified their holdings of the business. Empowered Funds LLC raised its holdings in Insmed by 32.6% during the 1st quarter. Empowered Funds LLC now owns 51,986 shares of the biopharmaceutical company’s stock worth $8,501,000 after buying an additional 12,775 shares during the period. Hsbc Holdings PLC lifted its stake in Insmed by 8,052.6% in the fourth quarter. Hsbc Holdings PLC now owns 123,267 shares of the biopharmaceutical company’s stock valued at $21,493,000 after buying an additional 121,755 shares in the last quarter. S&CO Inc. bought a new position in Insmed in the second quarter valued at approximately $1,386,000. C WorldWide Group Holding A S boosted its holdings in shares of Insmed by 62.1% in the second quarter. C WorldWide Group Holding A S now owns 261,110 shares of the biopharmaceutical company’s stock valued at $27,840,000 after buying an additional 100,000 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Insmed in the fourth quarter valued at approximately $1,901,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options.

Insmed’s principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients.